Midazolam half-life
Midazolam is modeled at 2.5 hours within the broad adult labeling range.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Midazolam: evidence and interpretation notes
The number behind the long tail
Midazolam is modeled at 2.5 hours within the broad adult labeling range. Age, critical illness, CYP3A interactions, and route can move the observed result enough that the center should never be read as universal.
A 2.5-hour input gives this profile one auditable line for Midazolam. The line deliberately stops short of claims about clinical effect, measured concentration, or testing results.
Midazolam may involve residual sedation, active metabolites, age-related differences, and co-medication effects. The curve is a parent-drug simplification, not a next-day impairment or withdrawal model.
What each source contributes
- DailyMed: MIDAZOLAM HYDROCHLORIDE SYRUP [PRECISION DOSE INC.]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Midazolam. This identity record confirms names and compound identity and does not supply a human half-life.
- Pharmacokinetics and drug metabolism in the elderly. This metabolism study identifies pathways, metabolites, or analytical targets and does not by itself create a complete human concentration-time curve.
For Midazolam, the numerical model is tied most closely to DailyMed: MIDAZOLAM HYDROCHLORIDE SYRUP [PRECISION DOSE INC.]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why the range stays visible
The 1.5-to-3-hour range is retained beside the 2.5-hour input for Midazolam. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 2.5 h as a representative input for Midazolam. In the simplified model, about 0.1% remains after 24 hours and about 3% remains after five half-lives, or roughly 12.5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
benzodiazepine context
Benzodiazepine half-life estimates can be especially sensitive to active metabolites, redistribution, age, liver function, and repeated use.
- A long terminal half-life does not mean effects remain constant for the whole period.
- Shorter-acting entries can still have residual effects after the main subjective effects fade.
- Repeated exposure can create overlap that a single-dose curve does not show.
ComparisonTimeline checkpoints and nearby profiles
Midazolam timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 18.9% | Long-tail portion of the model |
| 12 h | 3.59% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.13% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Midazolam within the benzodiazepine group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Temazepam (9 h)
- Alprazolam (11.2 h)
- Lorazepam (14 h)
- Diazepam (30 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 2.5 h |
|---|---|
| Reported range | 1.5 h to 3 h |
| Curve type | Normalized, first-order decline |
Selection note: Midazolam is modeled at 2.5 hours within the broad adult labeling range. Age, critical illness, CYP3A interactions, and route can move the observed result enough that the center should never be read as universal.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: MIDAZOLAM HYDROCHLORIDE SYRUP [PRECISION DOSE INC.].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Midazolam.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Pharmacokinetics and drug metabolism in the elderly.Metabolism-focused evidence used to identify pathways or analytes. It does not automatically establish a population half-life.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the benzodiazepine group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.